NCT02549040 - Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 21, 2015

Primary Completion Date

December 24, 2015

Study Completion Date

December 24, 2015

Conditions

Human Immunodeficiency Virus-1 (HIV-1)

Interventions

DRUG

Treatment A: Doravirine 100 mg film coated tablet

Single doravirine 100 mg film coated tablet administered orally at the start of Period 2

DRUG

Treatment B: Doravirine 150 mg tablet (40% drug loaded granule)

Single doravirine NF Type 1 dose (150 mg tablet \[40% drug loaded granule\]) administered orally at the start of Period 1

DRUG

Treatment C: Doravirine 150 mg tablet (30% drug loaded granule)

Single doravirine NF Type 2 dose (150 mg tablet \[30% drug loaded granule\])administered orally at the start of Period 3

DRUG

Treatment D: Doravirine 150 mg tablet (50% drug loaded granule)

Single doravirine NF Type 3 dose (150 mg tablet \[50% drug loaded granule\])administered orally at the start of Period 4

DRUG

Treatment E: Doravirine 100 mg tablet (30% drug loaded granule)

Single doravirine NF Type 4 dose (100 mg tablet \[30% drug loaded granule\]) administered orally at the start of Period 5

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY